Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"
- PMID: 33676577
- PMCID: PMC7936466
- DOI: 10.1186/s13722-021-00223-z
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)"
Abstract
Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications-methadone, buprenorphine, and extended-release injectable naltrexone,- are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited, in part due to poor rates of retention in treatment. In addition, minimum recovery milestones and other factors that influence when and whether individuals can safely discontinue medications are unknown. The National Drug Abuse Treatment Clinical Trials Network (CTN) study "Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy" (RDD; CTN-0100) will be among the largest clinical trials on treatment of OUD yet conducted, consisting of two phases, the Retention phase, and the Duration-Discontinuation phase. The Retention phase, open to patients initiating treatment, will test different doses and formulations of buprenorphine (standard dose sublingual, high dose sublingual, or extended-release injection), and a digital therapeutic app delivering contingency management and cognitive behavioral counseling on the primary outcome of retention in treatment. The Discontinuation phase, open to patients in stable remission from OUD and choosing to discontinue medication (including participants from the Retention phase or from the population of patients treated at the clinical site, referred by an outside prescriber or self-referred) will study different tapering strategies for buprenorphine (sublingual taper vs taper with injection buprenorphine), and a digital therapeutic app which provides resources to promote recovery, on the primary outcome of relapse-free discontinuation of medication. This paper describes how the RDD trial derives from two decades of research in the CTN. Initial trials (CTN-0001; CTN-0002; CTN-0003) focused on opioid detoxification, showing buprenorphine-naloxone was effective for detoxification, but that acute detoxification did not appear to be an effective treatment strategy. Trials on comparative effectiveness of medications for opioid use disorder (MOUD) (CTN-0027; CTN-0030; and CTN-0051) highlighted the problem of dropout from treatment and few trials defined retention on MOUD as the primary outcome. Long-term follow-up studies on those patient samples demonstrated the importance of long-term continuation of medication for many patients to sustain remission. Overall, these trials highlight the potential of a stable research infrastructure such as CTN to advance treatment effectiveness through a programmatic succession of large clinical trials.
Keywords: Buprenorphine; Clinical trials; Naltrexone; Opioid use disorder.
Conflict of interest statement
EVN served as unpaid consultant to Alkermes, Braeburn-Camurus and Pear Therapeutics and has received in-kind medication for studies from Reckitt/Indivior, Alkermes, and a therapeutic application from Pear Therapeutics for a study. RW has consulted to Takeda Pharmaceuticals, Analgesic Solutions, Astellas Pharma, and Cerevel Therapeutics. JR reports medication for the present study from Indivior and Braeburn, and medication and/or funds for other studies (as principal investigator or investigator) from Indivior and Alkermes. MS, PN, EC all have no competing interests to declare.
Figures
Similar articles
-
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.Contemp Clin Trials. 2024 Jul;142:107543. doi: 10.1016/j.cct.2024.107543. Epub 2024 Apr 23. Contemp Clin Trials. 2024. PMID: 38657730 Clinical Trial.
-
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3. J Subst Abuse Treat. 2018. PMID: 28733097 Free PMC article.
-
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.Contemp Clin Trials. 2016 Sep;50:253-64. doi: 10.1016/j.cct.2016.08.004. Epub 2016 Aug 10. Contemp Clin Trials. 2016. PMID: 27521809 Free PMC article. Clinical Trial.
-
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.Addict Behav. 2023 Apr;139:107589. doi: 10.1016/j.addbeh.2022.107589. Epub 2022 Dec 17. Addict Behav. 2023. PMID: 36565531 Review.
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
Cited by
-
Association of Cannabis Legalization with Cannabis Positive Drug Screening in US Veterans.medRxiv [Preprint]. 2023 Dec 9:2023.12.08.23299731. doi: 10.1101/2023.12.08.23299731. medRxiv. 2023. PMID: 38105937 Free PMC article. Preprint.
-
"Safer Drug Supply" Measures in Canada to Reduce the Drug Overdose Fatality Toll: Clarifying Concepts, Practices and Evidence Within a Public Health Intervention Framework.J Stud Alcohol Drugs. 2023 Nov;84(6):801-807. doi: 10.15288/jsad.23-00195. Epub 2023 Oct 3. J Stud Alcohol Drugs. 2023. PMID: 37796625
-
Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.Int J Drug Policy. 2023 Aug;118:104120. doi: 10.1016/j.drugpo.2023.104120. Epub 2023 Jul 8. Int J Drug Policy. 2023. PMID: 37429162
-
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.Drug Alcohol Depend Rep. 2023 Jan 10;6:100133. doi: 10.1016/j.dadr.2023.100133. eCollection 2023 Mar. Drug Alcohol Depend Rep. 2023. PMID: 36994370 Free PMC article. Review.
-
Integrating peer support services into primary care-based OUD treatment: Lessons from the Penn integrated model.Healthc (Amst). 2022 Sep;10(3):100641. doi: 10.1016/j.hjdsi.2022.100641. Epub 2022 Jul 2. Healthc (Amst). 2022. PMID: 35785613 Free PMC article.
References
-
- Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2019;393(10173):778–790. doi: 10.1016/S0140-6736(18)32259-1. - DOI - PubMed
-
- Knopf A. Sublocade trial data published: better than placebo. Alcohol Drug Abuse Wkly. 2019;31(8):4–4. doi: 10.1002/adaw.32270. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical